{"gene":"PLTP","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":1995,"finding":"Recombinant human and mouse PLTP expressed in BHK cells possesses both phospholipid transfer activity and HDL conversion activity, demonstrating these are intrinsic functions of the PLTP protein. PLTP converts distinct HDL subspecies (Lp(A-I) and Lp(A-I/A-II)) into populations of larger and smaller particles.","method":"Eukaryotic cell expression of recombinant PLTP, functional assays for phospholipid transfer and HDL conversion","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — reconstituted recombinant protein with direct functional assays, foundational study","pmids":["7654777"],"is_preprint":false},{"year":1998,"finding":"PLTP binds to both apoA-I and apoA-II, and the PLTP-binding domain on apoA-I resides in the amino-terminal region (residues 27–141), as demonstrated by solid-phase ligand binding assay, ELISA, apolipoprotein affinity chromatography, and monoclonal antibody epitope mapping.","method":"Solid-phase ligand binding assay, ELISA, affinity chromatography, monoclonal antibody inhibition studies","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal binding methods in a single study","pmids":["9469594"],"is_preprint":false},{"year":1999,"finding":"Molecular modeling of PLTP based on BPI crystal structure predicts a two-domain architecture with conserved N-terminal and C-terminal lipid-binding pockets. Site-directed mutagenesis of residues in these pockets abolishes phospholipid transfer activity. The N-terminal pocket mutants show reduced activity without altered HDL binding, while C-terminal pocket may mediate HDL association. A disulfide bridge between Cys146 and Cys185 is structurally essential.","method":"Homology modeling, site-directed mutagenesis, transient expression in HeLa cells, solid-phase HDL-binding assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — structure-guided mutagenesis with functional assays, multiple orthogonal methods","pmids":["10357844"],"is_preprint":false},{"year":1999,"finding":"PLTP has an inherent serine esterase-type protease activity that cleaves apoA-I in the C-terminal portion between residues Ala196 and Thr197, generating a 23 kDa N-terminal fragment. The cleavage is inhibited by APMSF and chymostatin, and is reproduced by recombinant PLTP from CHO cells and baculovirus-insect cell systems.","method":"SDS-PAGE, Western blot, mass spectrometry, N-terminal sequencing, protease inhibitor studies, recombinant PLTP","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical assay with mass spectrometry confirmation and multiple recombinant sources","pmids":["10191289"],"is_preprint":false},{"year":2000,"finding":"Phospholipid transfer by PLTP is a prerequisite for PLTP-mediated HDL conversion. Chemical modification (DEPC or EMTS) of PLTP reduces both phospholipid transfer and HDL conversion activities in parallel. Recombinant N-terminal pocket mutants defective in phospholipid transfer cannot release apoA-I from HDL3 or generate prebeta-HDL.","method":"Chemical modification of PLTP, recombinant mutant proteins, native gradient gel electrophoresis, ultracentrifugation, crossed immunoelectrophoresis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — chemical and genetic ablation of activity with multiple orthogonal readouts","pmids":["11123937"],"is_preprint":false},{"year":2002,"finding":"Human plasma PLTP exists as two distinct forms: a high-activity form (HA-PLTP, ~160 kDa) associated with apoE and a low-activity form (LA-PLTP, ~520 kDa) complexed with apoA-I. The two forms differ in heparin-binding affinity and can be separated chromatographically.","method":"Heparin-Sepharose chromatography, gel filtration, SDS-PAGE, Western blot, immunoprecipitation, anti-apoE and anti-apoA-I immunoaffinity chromatography","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal purification and identification methods","pmids":["11854286"],"is_preprint":false},{"year":2002,"finding":"PLTP is a direct transcriptional target of LXR (liver X receptor): two functional LXR response elements (LXREs) were identified in the proximal promoter of the human PLTP gene, one a canonical DR4 and one a novel inverted repeat separated by 1 bp that also serves as an FXR response element.","method":"Affymetrix microarray, Northern blot, promoter LXRE characterization and reporter assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — functional promoter elements characterized with multiple assays","pmids":["12454263"],"is_preprint":false},{"year":2003,"finding":"HepG2-secreted PLTP co-elutes with apoE on gel filtration (~160 kDa), co-purifies with apoE on anti-apoE immunoaffinity chromatography, and anti-apoE antibodies inhibit PLTP activity, establishing a physical and functional interaction between PLTP and apoE in hepatic cells.","method":"Heparin-Sepharose affinity chromatography, size-exclusion chromatography, anti-apoE immunoaffinity chromatography, antibody inhibition of PLTP activity","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — multiple chromatographic methods plus functional inhibition assay","pmids":["12810820"],"is_preprint":false},{"year":2003,"finding":"Mast cell chymase degrades PLTP into specific fragments (70, 52, 48, 31 kDa), reducing both PLTP-mediated phospholipid transfer activity and pre-beta-HDL generation. Chymase also degrades PLTP-generated pre-beta-HDL particles, impairing high-affinity cholesterol efflux from macrophage foam cells.","method":"Immunoblot, phospholipid transfer assay, native gel electrophoresis, cholesterol efflux assay from foam cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic cleavage with defined functional consequences at multiple endpoints","pmids":["12531890"],"is_preprint":false},{"year":2004,"finding":"PLTP functions as a transfer factor for alpha-tocopherol (vitamin E) in the brain. PLTP-deficient mice show significant brain alpha-tocopherol depletion, elevated oxidative stress markers (lipofuscin, cholesterol oxides, cellular peroxides), and increased anxiety behavior, establishing PLTP's role in brain vitamin E transport.","method":"PLTP knockout mouse model, alpha-tocopherol quantification, lipofuscin and cholesterol oxide measurement, elevated plus-maze behavioral testing","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with multiple biochemical and behavioral readouts","pmids":["15576481"],"is_preprint":false},{"year":2005,"finding":"Exogenous recombinant PLTP added to primary human astrocytes significantly increases apoE secretion into conditioned medium, demonstrating that PLTP can regulate apoE secretion in brain cells.","method":"Recombinant PLTP treatment of primary human astrocyte cultures, PLTP activity assay, anti-apoE immunoaffinity chromatography, Western blot","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 — direct cell treatment experiment with single functional readout","pmids":["15795933"],"is_preprint":false},{"year":2008,"finding":"Phospholipid transfer activity of PLTP is essential for atherogenesis: mice expressing a mutant PLTP that associates with HDL but lacks transfer activity show no change in HDL lipids, no stimulation of hepatic VLDL-TG secretion, and no increase in atherosclerotic lesion size, unlike mice expressing wild-type PLTP.","method":"Transgenic mice expressing transfer-inactive PLTP mutant, plasma lipid measurements, VLDL secretion assay, atherosclerosis quantification","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with activity-null mutant, multiple phenotypic readouts","pmids":["18711210"],"is_preprint":false},{"year":2008,"finding":"Elevation of systemic PLTP (transgenic overexpression) impairs macrophage reverse cholesterol transport (RCT) in vivo, reducing plasma and fecal 3H-cholesterol tracer levels. Elevation of macrophage-specific PLTP alone does not affect RCT, indicating the systemic PLTP pool drives the impairment.","method":"In vivo RCT assay with 3H-cholesterol-loaded macrophages, PLTP transgenic and macrophage transplantation models, radioactivity quantification in plasma/liver/feces","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 2 — in vivo RCT assay with cell-specific transplantation controls","pmids":["19100548"],"is_preprint":false},{"year":2008,"finding":"Acute elevation of plasma PLTP activity in LDLR-knockout mice inhibits VLDL catabolism (at least partly by decreasing lipoprotein lipase activity), increases plasma VLDL-triglyceride levels, decreases HDL, and accelerates progression and destabilization of pre-existing atherosclerotic lesions.","method":"Conditional Tet-On transgenic mouse model, VLDL secretion assay, lipoprotein lipase activity measurement, atherosclerosis quantification, lesion composition analysis","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 — inducible transgenic model with mechanistic VLDL/LPL readouts","pmids":["18421000"],"is_preprint":false},{"year":2009,"finding":"PLTP localizes to the nucleus of neuroblastoma cells, cortical neurons, and transfected CHO/BHK cells. Nuclear export of PLTP is CRM1-dependent (blocked by leptomycin B). Secreted extracellular PLTP can enter cells and translocate to the nucleus, where it remains phospholipid transfer-active.","method":"Subcellular fractionation, leptomycin B inhibition, live-cell imaging, phospholipid transfer activity assay of nuclear fractions","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional assay and pharmacological inhibition, single lab","pmids":["19321130"],"is_preprint":false},{"year":2011,"finding":"PLTP (wild-type and lipid-transfer-inactive mutant PLTPM159E) increases nuclear levels of active pSTAT3(Tyr705) in macrophages via an ABCA1-dependent mechanism, and reduces nuclear NFκB p65 levels and pro-inflammatory cytokine secretion, demonstrating lipid-transfer-independent anti-inflammatory signaling.","method":"Recombinant wild-type and mutant PLTP treatment of differentiated THP1 cells and primary macrophages, nuclear fractionation, ABCA1 chemical inhibition and siRNA knockdown, ELISA for cytokines","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — activity-null mutant distinguishes lipid transfer from signaling, ABCA1 confirmed by two knockdown methods","pmids":["21782857"],"is_preprint":false},{"year":2012,"finding":"Liver-specific PLTP expression in PLTP-null mice dramatically increases plasma non-HDL cholesterol, phospholipids, triglycerides, and apoB levels by enhancing VLDL lipidation in the hepatocyte microsomal lumen and increasing VLDL secretion, without affecting HDL lipids.","method":"Adenovirus-mediated liver-specific PLTP expression in PLTP-null mice, VLDL lipidation assay in hepatocyte microsomes, plasma VLDL secretion assay","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — organ-specific rescue experiment with direct mechanistic readout (microsomal VLDL lipidation)","pmids":["22367708"],"is_preprint":false},{"year":2014,"finding":"Cathepsin G (a serine protease) cleaves and inactivates PLTP in COPD bronchoalveolar lavage fluid. PLTP silencing (siRNA) in mice prior to LPS challenge increases ERK and NF-κB activation and pro-inflammatory cytokine levels; conversely, recombinant PLTP administration counters these effects, establishing an anti-inflammatory role for lung PLTP.","method":"BALF proteolytic activity assay, PLTP siRNA in mouse lungs, recombinant PLTP administration, ERK/NF-κB western blot, cytokine measurement, LPS lung injury model","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1/2 — loss-of-function and gain-of-function in vivo with mechanistic pathway readout, cathepsin G identified as the protease","pmids":["24532668"],"is_preprint":false},{"year":2014,"finding":"PLTP deficiency increases BBB permeability in mice, decreases tight junction proteins (occludin, ZO-1, claudin-5), and elevates cerebrovascular ROS and lipid peroxidation. Dietary vitamin E supplementation in PLTP-KO mice restores BBB integrity and tight junction protein expression by reducing oxidative stress, linking PLTP's vitamin E transfer activity to BBB maintenance.","method":"In vivo multiphoton imaging, Evans blue assay, western blot for tight junction proteins, ROS and lipid peroxidation measurements, vitamin E dietary supplementation rescue","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — KO phenotype with dietary rescue linking mechanism to vitamin E transfer","pmids":["24513285"],"is_preprint":false},{"year":2015,"finding":"PLTP deficiency in APP/PS1ΔE9 Alzheimer's model mice increases β-secretase activity and expression of γ-secretase catalytic units, shifts APP processing toward the amyloidogenic pathway, increases soluble Aβ peptides, and accelerates memory dysfunction, placing PLTP as a regulator of APP processing.","method":"PLTP/APP/PS1 double-knockout mouse model, β- and γ-secretase activity assays, Aβ ELISA, western blot, Morris water maze","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with direct secretase activity measurement, single study","pmids":["26160914"],"is_preprint":false},{"year":2015,"finding":"PLTP deficiency in mice shifts CD4+ Th0 cell polarization toward the anti-inflammatory Th2 phenotype and significantly decreases production of the pro-Th1 cytokine IL-18 by accessory cells, establishing PLTP as a regulator of adaptive immune T-helper cell polarization.","method":"PLTP-KO mouse model, contact hypersensitivity model (DNFB), flow cytometry for T-cell subsets, cytokine measurements","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — KO with defined immunological readouts and in vivo challenge model, single lab","pmids":["26320740"],"is_preprint":false},{"year":2018,"finding":"Electron microscopy reveals PLTP has a banana-shaped structure similar to CETP. PLTP penetrates into both HDL and LDL surfaces and forms a ternary PLTP-HDL-LDL complex, providing structural basis for the phospholipid transfer mechanism between lipoproteins.","method":"Electron microscopy (multiple EM techniques), single-particle analysis, lipoprotein interaction studies","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 1 — structural EM study with functional interaction data, single study without mutagenesis validation","pmids":["29883800"],"is_preprint":false},{"year":2018,"finding":"Both lipid-transfer-active and -inactive forms of recombinant PLTP directly stimulate pro-inflammatory cytokine production (IL-8, IL-6, VEGF, MMP3) and proliferation of rheumatoid arthritis fibroblast-like synoviocytes (FLS) via ABCA1 and STAT3 pathway activation, independently of lipid transfer activity.","method":"Recombinant active and inactive PLTP treatment of RA-FLS, ELISA for cytokines, 3H-thymidine proliferation assay, flow cytometry for ABCA1, STAT3 activation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — activity-null mutant used to dissect lipid transfer from signaling, multiple cytokine readouts","pmids":["29565987"],"is_preprint":false},{"year":2019,"finding":"PLTP deficiency protects mice from high-fat-diet-induced obesity and insulin resistance by enhancing insulin receptor and Akt phosphorylation in liver, adipose, and muscle, increasing GLUT4 in plasma membranes of adipocytes and muscle cells after insulin stimulation, and reducing sphingomyelins and free cholesterol in lipid rafts of hepatocyte plasma membranes.","method":"PLTP-KO mice on high-fat diet, western blot for insulin receptor/Akt phosphorylation, GLUT4 plasma membrane fractionation, lipid raft lipid composition analysis","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 — KO model with multiple mechanistic readouts including lipid raft composition, single lab","pmids":["31220615"],"is_preprint":false},{"year":2020,"finding":"PLTP is identified as a batokine secreted by brown adipose tissue (BAT). Systemic or BAT-specific PLTP overexpression improves glucose tolerance, insulin sensitivity, and energy expenditure, and decreases plasma cholesterol/phospholipids/sphingolipids. The mechanism involves increased circulating bile acids that in turn enhance glucose uptake and thermogenesis in BAT, establishing PLTP as a mediator of BAT-liver interorgan communication.","method":"Proteomics/transcriptomics of human thermogenic adipocytes, BAT-specific and systemic PLTP overexpression mouse models, bile acid measurement, glucose tolerance and insulin sensitivity tests","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 — organ-specific overexpression with multi-organ metabolic readouts and identification of bile acid intermediary","pmids":["32672883"],"is_preprint":false},{"year":2022,"finding":"PLTP is a direct transcriptional target of p53; its transactivation is impaired by cancer-associated p53 hypomorphs (P47S, Y107H, G334R). Enforced PLTP expression suppresses colony formation in human tumor cell lines and regulates cellular sensitivity to ferroptosis.","method":"RNA-seq in lymphoblastoid cell lines, p53 hypomorph comparison, PLTP overexpression colony formation assay, ferroptosis sensitivity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple p53 hypomorphs tested, direct p53-PLTP transcriptional link with functional cancer readouts","pmids":["36309086"],"is_preprint":false},{"year":2012,"finding":"CSE-induced TGF-β1 production and Smad3 phosphorylation in human alveolar epithelial cells is mediated through a Ras/ERK/PLTP pathway: ERK inhibition suppresses PLTP expression and TGF-β1 production; PLTP siRNA suppresses TGF-β1 and Smad3 activation downstream of ERK, without affecting Ras/ERK itself.","method":"ERK inhibitors, PLTP siRNA, Smad3 phosphorylation western blot, TGF-β1 ELISA in A549 cells","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by siRNA at defined pathway position, single lab","pmids":["22034170"],"is_preprint":false},{"year":2021,"finding":"In vivo tracer studies using Orbitrap Lumos mass spectrometry show that PLTP is secreted in medium and large HDL (alpha2, alpha1, alpha0) and is transferred from medium to larger HDL sizes during circulation, from where it is catabolized.","method":"In vivo stable isotope tracer kinetics, targeted mass spectrometry (Orbitrap Lumos), compartmental modeling","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 1/2 — in vivo metabolic tracing with compartmental modeling, novel metabolic pathway placement","pmids":["33351780"],"is_preprint":false},{"year":2025,"finding":"In diabetic retinopathy, PLTP promoter DNA hypermethylation mediated by DNMT3B suppresses PLTP expression in retinal endothelial cells. PLTP overexpression reverses high-glucose-induced impairment of endothelial migration and tube formation by promoting AKT and GSK3β phosphorylation, identifying PLTP as a regulator of retinal vascular function via the AKT/GSK3β pathway.","method":"siRNA for DNMT3B, luciferase reporter assay, PLTP overexpression in HRMECs, tube formation/migration assays, coimmunoprecipitation, GSK3β inhibitor, transcriptome sequencing","journal":"Clinical epigenetics","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in a single study identifying DNMT3B as writer and AKT/GSK3β as downstream pathway","pmids":["40380281"],"is_preprint":false},{"year":2025,"finding":"PLTP promotes M2 macrophage polarization in hepatocellular carcinoma by binding to AURKA and p65, forming a ternary complex that induces p65 phosphorylation, activating NF-κB and upregulating IL-6, IL-8, and CSF-1. The PLTP functional domain (residues 25–245) mediates these interactions.","method":"Molecular docking, proteomics, coimmunoprecipitation, biochemical assays, PLTP overexpression in HCC, in vivo mouse models","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal co-IP and molecular docking with in vivo validation, single lab","pmids":["41391040"],"is_preprint":false},{"year":2010,"finding":"ApoA-I (and apolipoproteins E, A-II, A-IV) enhances PLTP phospholipid transfer activity in a concentration-dependent manner without affecting PLTP secretion or mass from macrophage foam cells, and protects PLTP from heat inactivation.","method":"THP-1 macrophage foam cell model, PLTP activity assay, PLTP mass ELISA, recombinant apolipoprotein addition","journal":"Lipids in health and disease","confidence":"Medium","confidence_rationale":"Tier 3 — cell culture experiment with activity readout, mechanism of activation not fully resolved","pmids":["20534134"],"is_preprint":false}],"current_model":"PLTP is a plasma glycoprotein with a two-domain, lipid-binding-pocket structure (similar to BPI/CETP) that transfers phospholipids between lipoproteins by forming ternary PLTP-HDL-LDL complexes; its N-terminal pocket drives phospholipid transfer (a prerequisite for HDL conversion into larger fusion particles and prebeta-HDL), while its C-terminal pocket mediates HDL binding via apoA-I (residues 27–141) and apoE; PLTP circulates as a high-activity (~160 kDa, apoE-associated) and a low-activity (~520 kDa, apoA-I-associated) form, is a direct transcriptional target of LXR, FXR, and p53, drives hepatic VLDL production, transfers alpha-tocopherol to the brain and across the BBB, neutralizes and transfers LPS to lipoproteins, activates STAT3 and suppresses NF-κB in macrophages via ABCA1 in a lipid-transfer-independent manner, modulates CD4+ T-helper cell polarization, and in cancer contexts promotes NF-κB activation through a PLTP-AURKA-p65 complex and regulates ferroptosis sensitivity downstream of p53."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing that phospholipid transfer and HDL conversion are intrinsic activities of the PLTP protein resolved whether these were separable plasma functions or properties of a single gene product.","evidence":"Recombinant human/mouse PLTP expressed in BHK cells reconstituted both activities in vitro","pmids":["7654777"],"confidence":"High","gaps":["Structural basis for dual activity unknown","Relationship between phospholipid transfer and HDL conversion not yet causally ordered"]},{"year":1998,"claim":"Mapping the PLTP-binding domain on apoA-I to residues 27–141 identified the molecular interface through which PLTP engages its principal HDL-associated apolipoprotein partner.","evidence":"Solid-phase binding, ELISA, affinity chromatography, and monoclonal antibody epitope mapping","pmids":["9469594"],"confidence":"High","gaps":["Reciprocal mapping of the apoA-I-binding site on PLTP not determined","Structural resolution of the PLTP–apoA-I complex lacking"]},{"year":1999,"claim":"Homology modeling and site-directed mutagenesis established PLTP's two-domain BPI-like architecture and demonstrated that both N- and C-terminal lipid-binding pockets are functionally required, with the N-terminal pocket driving phospholipid transfer and the C-terminal pocket mediating HDL binding.","evidence":"Structure-guided mutagenesis of lipid-pocket residues in HeLa-expressed PLTP, solid-phase HDL-binding assay","pmids":["10357844"],"confidence":"High","gaps":["No crystal structure of PLTP itself","Contribution of the C-terminal pocket to transfer vs. binding not fully delineated"]},{"year":1999,"claim":"Discovery of an intrinsic serine esterase-type protease activity in PLTP that cleaves apoA-I at Ala196–Thr197 revealed an unexpected catalytic function beyond lipid transfer.","evidence":"Mass spectrometry, N-terminal sequencing, and protease inhibitor studies on recombinant PLTP from multiple expression systems","pmids":["10191289"],"confidence":"High","gaps":["Physiological significance of apoA-I cleavage in vivo undetermined","Active-site residues responsible for protease activity not identified"]},{"year":2000,"claim":"Demonstrating that phospholipid transfer is a prerequisite for HDL conversion causally ordered PLTP's two activities: lipid transfer must occur before apoA-I release and prebeta-HDL generation.","evidence":"Chemical modification and N-terminal pocket mutants abolished both transfer and HDL conversion in parallel","pmids":["11123937"],"confidence":"High","gaps":["Kinetic mechanism of coupled transfer-to-conversion not resolved","Whether intermediate lipid species are required not tested"]},{"year":2002,"claim":"Resolution of two circulating PLTP forms—a high-activity ~160 kDa apoE-associated form and a low-activity ~520 kDa apoA-I-associated form—explained the long-standing discrepancy between PLTP mass and activity measurements in plasma.","evidence":"Heparin-Sepharose and gel filtration chromatography, immunoaffinity separation with anti-apoE/anti-apoA-I","pmids":["11854286","12810820"],"confidence":"High","gaps":["What converts HA-PLTP to LA-PLTP is unknown","Whether the two forms have distinct tissue origins not established"]},{"year":2002,"claim":"Identification of functional LXR and FXR response elements in the PLTP promoter placed PLTP under direct nuclear receptor transcriptional control, connecting its expression to cholesterol/bile acid sensing.","evidence":"Microarray, Northern blot, and promoter-reporter assays in human cells","pmids":["12454263"],"confidence":"High","gaps":["Tissue-specific transcriptional regulation not fully characterized","Relative contribution of LXR vs. FXR in different tissues unknown"]},{"year":2004,"claim":"PLTP-knockout mice revealed a non-redundant role for PLTP in brain alpha-tocopherol delivery, with deficiency causing vitamin E depletion, oxidative stress, and behavioral abnormalities.","evidence":"PLTP-KO mouse model with alpha-tocopherol quantification, oxidative stress markers, and elevated plus-maze testing","pmids":["15576481"],"confidence":"High","gaps":["Whether PLTP transfers vitamin E across the BBB directly or via lipoproteins not resolved","CNS cell types responsible for PLTP-mediated vitamin E transport not identified"]},{"year":2008,"claim":"In vivo studies using transfer-inactive PLTP mutant mice and PLTP transgenic mice established that phospholipid transfer activity is required for PLTP's pro-atherogenic effects including stimulation of hepatic VLDL secretion, impairment of reverse cholesterol transport, and atherosclerotic lesion progression.","evidence":"Transfer-inactive PLTP mutant transgenic mice, PLTP overexpression models, in vivo RCT assay, VLDL secretion, and atherosclerosis quantification","pmids":["18711210","19100548","18421000"],"confidence":"High","gaps":["Molecular mechanism by which PLTP stimulates VLDL lipidation not resolved at the protein level","Whether transfer activity is also required for anti-inflammatory signaling not tested in vivo"]},{"year":2011,"claim":"Demonstration that both active and transfer-inactive PLTP activate STAT3 and suppress NF-κB in macrophages via ABCA1 uncovered a lipid-transfer-independent signaling function, separating PLTP's metabolic and immunomodulatory roles.","evidence":"Wild-type and M159E mutant PLTP treatment of THP1 and primary macrophages, ABCA1 siRNA and chemical inhibition, nuclear fractionation","pmids":["21782857"],"confidence":"High","gaps":["How PLTP engages ABCA1 to activate STAT3 mechanistically unknown","Whether this signaling operates in vivo under physiological conditions not shown"]},{"year":2012,"claim":"Liver-specific PLTP rescue in PLTP-null mice showed that hepatic PLTP drives VLDL lipidation in the microsomal lumen and VLDL secretion without affecting HDL, establishing the liver as the primary tissue for PLTP's pro-atherogenic VLDL effects.","evidence":"Adenovirus-mediated liver-specific PLTP expression, hepatocyte microsomal VLDL lipidation assay","pmids":["22367708"],"confidence":"High","gaps":["Whether PLTP acts on apoB directly or via an intermediary lipid donor in the ER lumen unknown","Contribution of intestinal PLTP to VLDL metabolism not addressed"]},{"year":2014,"claim":"In vivo loss- and gain-of-function experiments in lung established PLTP as an anti-inflammatory factor degraded by cathepsin G in COPD, bridging PLTP's lipid transfer function with innate immune regulation in the airway.","evidence":"PLTP siRNA and recombinant PLTP in mouse LPS lung injury model, cathepsin G cleavage of PLTP in BALF","pmids":["24532668"],"confidence":"High","gaps":["Whether anti-inflammatory lung function is lipid-transfer-dependent or ABCA1/STAT3-dependent not distinguished","PLTP's substrate in the lung (LPS, surfactant phospholipids) not resolved"]},{"year":2014,"claim":"Linking PLTP deficiency to BBB breakdown via reduced tight junction proteins and oxidative stress—rescued by dietary vitamin E—provided a mechanistic chain from PLTP's vitamin E transfer activity to cerebrovascular integrity.","evidence":"Multiphoton imaging, Evans blue permeability assay, tight junction protein western blot, vitamin E dietary rescue in PLTP-KO mice","pmids":["24513285"],"confidence":"Medium","gaps":["Direct measurement of PLTP-mediated vitamin E transport across BBB endothelium not performed","Whether tight junction loss is a direct or secondary consequence of oxidative stress not resolved"]},{"year":2015,"claim":"PLTP deficiency shifted CD4+ T-helper polarization toward Th2 and reduced IL-18, establishing PLTP as a modulator of adaptive immunity beyond its known innate immune roles.","evidence":"PLTP-KO mouse contact hypersensitivity model, flow cytometry for T-cell subsets, cytokine measurements","pmids":["26320740"],"confidence":"Medium","gaps":["Whether effect on Th polarization is cell-autonomous or mediated by accessory cell lipid changes not resolved","Molecular mechanism linking PLTP to IL-18 production unknown"]},{"year":2018,"claim":"Electron microscopy visualization of PLTP's banana-shaped structure and its ternary complex with HDL and LDL provided the first direct structural basis for the shuttle transfer mechanism between lipoproteins.","evidence":"Single-particle EM analysis of PLTP and PLTP–lipoprotein complexes","pmids":["29883800"],"confidence":"Medium","gaps":["Atomic-resolution structure not available","Whether the ternary complex is an obligate intermediate or one of multiple transfer modes not established"]},{"year":2020,"claim":"Identification of PLTP as a batokine secreted by brown adipose tissue that improves systemic glucose tolerance through bile acid-mediated interorgan signaling expanded PLTP's metabolic role beyond lipoprotein metabolism.","evidence":"Proteomics of human thermogenic adipocytes, BAT-specific PLTP overexpression mice, bile acid measurements, glucose tolerance tests","pmids":["32672883"],"confidence":"Medium","gaps":["Mechanism by which PLTP increases bile acid levels not determined","Whether BAT-derived PLTP acts on hepatic VLDL secretion not tested"]},{"year":2022,"claim":"Establishing PLTP as a direct p53 transcriptional target that suppresses colony formation and regulates ferroptosis sensitivity connected PLTP to tumor suppression pathways beyond lipid metabolism.","evidence":"RNA-seq in lymphoblastoid cell lines with p53 hypomorphs, PLTP overexpression colony formation and ferroptosis assays","pmids":["36309086"],"confidence":"Medium","gaps":["Mechanism of ferroptosis regulation by PLTP (lipid peroxidation vs. iron) not resolved","Whether PLTP tumor-suppressive function operates in vivo not tested"]},{"year":2025,"claim":"Discovery of a PLTP–AURKA–p65 ternary complex that activates NF-κB in hepatocellular carcinoma revealed that PLTP can also promote—not just suppress—NF-κB signaling in a context-dependent manner, driving M2 macrophage polarization and tumor-associated inflammation.","evidence":"Reciprocal co-IP, molecular docking, proteomics, PLTP overexpression in HCC cells and mouse tumor models","pmids":["41391040"],"confidence":"Medium","gaps":["Apparent contradiction with anti-inflammatory NF-κB suppression in macrophages not reconciled","Whether AURKA kinase activity is required for the PLTP-mediated p65 activation not tested","Single-lab finding awaiting independent replication"]},{"year":2025,"claim":"Identification of DNMT3B-mediated promoter hypermethylation as a mechanism silencing PLTP in diabetic retinopathy, with downstream AKT/GSK3β signaling rescuing endothelial dysfunction, added an epigenetic regulatory layer to PLTP biology.","evidence":"DNMT3B siRNA, luciferase reporter, PLTP overexpression in HRMECs, tube formation/migration assays","pmids":["40380281"],"confidence":"Medium","gaps":["Whether PLTP activates AKT directly or through an intermediary receptor unknown","In vivo validation in diabetic retinopathy models not reported"]},{"year":null,"claim":"The atomic-resolution structure of PLTP, the mechanism by which PLTP engages ABCA1 to trigger STAT3 signaling independently of lipid transfer, and the basis for context-dependent NF-κB activation versus suppression remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution crystal or cryo-EM structure of human PLTP","ABCA1–PLTP signaling interface uncharacterized","Context determinants for pro- vs. anti-inflammatory NF-κB outcomes unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,2,4,9,11]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,4,16]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[15,22,29]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,5,7,21,27]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[14]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,4,5,9,11,16,24,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,22,26,28,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,20,29]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,25]}],"complexes":[],"partners":["APOA1","APOE","ABCA1","AURKA","RELA"],"other_free_text":[]},"mechanistic_narrative":"PLTP is a secreted lipid transfer glycoprotein that shuttles phospholipids and alpha-tocopherol between lipoproteins and across tissue barriers, functioning as a central regulator of HDL remodeling, hepatic VLDL assembly, brain vitamin E homeostasis, and innate/adaptive immune signaling. Its banana-shaped, two-domain architecture contains an N-terminal lipid-binding pocket essential for phospholipid transfer—a prerequisite for HDL conversion into larger fusion particles and prebeta-HDL generation—and a C-terminal pocket that mediates HDL association via apoA-I (residues 27–141) and apoE, with PLTP circulating as a high-activity (~160 kDa, apoE-associated) and a low-activity (~520 kDa, apoA-I-associated) form [PMID:10357844, PMID:11123937, PMID:9469594, PMID:11854286, PMID:29883800]. Beyond lipid transfer, PLTP activates STAT3 and suppresses NF-κB in macrophages through an ABCA1-dependent, lipid-transfer-independent signaling mechanism, modulates CD4+ T-helper cell polarization, and in hepatocellular carcinoma forms a ternary complex with AURKA and NF-κB p65 to drive pro-inflammatory cytokine expression [PMID:21782857, PMID:26320740, PMID:41391040]. PLTP is transcriptionally regulated by LXR, FXR, and p53, and its expression is epigenetically silenced by DNMT3B-mediated promoter hypermethylation in diabetic retinopathy, where it promotes endothelial function via AKT/GSK3β signaling [PMID:12454263, PMID:36309086, PMID:40380281]."},"prefetch_data":{"uniprot":{"accession":"P55058","full_name":"Phospholipid transfer protein","aliases":["Lipid transfer protein II"],"length_aa":493,"mass_kda":54.7,"function":"Mediates the transfer of phospholipids and free cholesterol from triglyceride-rich lipoproteins (low density lipoproteins or LDL and very low density lipoproteins or VLDL) into high-density lipoproteins (HDL) as well as the exchange of phospholipids between triglyceride-rich lipoproteins themselves (PubMed:11013307, PubMed:19321130, PubMed:21515415, PubMed:29883800, PubMed:7654777, PubMed:9132017). Facilitates the transfer of a spectrum of different lipid molecules, including diacylglycerol, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, cerebroside and phosphatidyl ethanolamine (PubMed:9132017). Plays an important role in HDL remodeling which involves modulating the size and composition of HDL (PubMed:29883800). Also plays a key role in the uptake of cholesterol from peripheral cells and tissues that is subsequently transported to the liver for degradation and excretion (PubMed:21736953). Two distinct forms of PLTP exist in plasma: an active form that can transfer phosphatidylcholine from phospholipid vesicles to HDL, and an inactive form that lacks this capability (PubMed:11013307)","subcellular_location":"Secreted; Nucleus","url":"https://www.uniprot.org/uniprotkb/P55058/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLTP","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLTP","total_profiled":1310},"omim":[{"mim_id":"615334","title":"CERAMIDE SYNTHASE 4; CERS4","url":"https://www.omim.org/entry/615334"},{"mim_id":"609708","title":"LIPOPROTEIN LIPASE; LPL","url":"https://www.omim.org/entry/609708"},{"mim_id":"607412","title":"BPI FOLD-CONTAINING PROTEIN, FAMILY A, MEMBER 1; BPIFA1","url":"https://www.omim.org/entry/607412"},{"mim_id":"606613","title":"HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1; HDLCQ1","url":"https://www.omim.org/entry/606613"},{"mim_id":"602274","title":"UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 2; GALNT2","url":"https://www.omim.org/entry/602274"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PLTP"},"hgnc":{"alias_symbol":["BPIFE"],"prev_symbol":[]},"alphafold":{"accession":"P55058","domains":[{"cath_id":"3.15.20.10","chopping":"19-29_209-286_439-475","consensus_level":"medium","plddt":95.4731,"start":19,"end":475},{"cath_id":"3.15.10.10","chopping":"50-202","consensus_level":"high","plddt":89.4346,"start":50,"end":202},{"cath_id":"3.15.20.10","chopping":"287-427","consensus_level":"medium","plddt":92.1811,"start":287,"end":427}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55058","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55058-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55058-F1-predicted_aligned_error_v6.png","plddt_mean":89.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLTP","jax_strain_url":"https://www.jax.org/strain/search?query=PLTP"},"sequence":{"accession":"P55058","fasta_url":"https://rest.uniprot.org/uniprotkb/P55058.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55058/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55058"}},"corpus_meta":[{"pmid":"11254896","id":"PMC_11254896","title":"The impact of phospholipid transfer protein (PLTP) on HDL metabolism.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11254896","citation_count":188,"is_preprint":false},{"pmid":"7654777","id":"PMC_7654777","title":"Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies.","date":"1995","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7654777","citation_count":120,"is_preprint":false},{"pmid":"12454263","id":"PMC_12454263","title":"Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12454263","citation_count":108,"is_preprint":false},{"pmid":"15576481","id":"PMC_15576481","title":"Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice.","date":"2004","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15576481","citation_count":93,"is_preprint":false},{"pmid":"11854286","id":"PMC_11854286","title":"Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP).","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11854286","citation_count":69,"is_preprint":false},{"pmid":"21787334","id":"PMC_21787334","title":"Plasma PLTP (phospholipid-transfer protein): an emerging role in 'reverse lipopolysaccharide transport' and innate immunity.","date":"2011","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/21787334","citation_count":61,"is_preprint":false},{"pmid":"10924722","id":"PMC_10924722","title":"Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity.","date":"2000","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10924722","citation_count":61,"is_preprint":false},{"pmid":"15258196","id":"PMC_15258196","title":"PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15258196","citation_count":58,"is_preprint":false},{"pmid":"9441745","id":"PMC_9441745","title":"Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9441745","citation_count":58,"is_preprint":false},{"pmid":"19413703","id":"PMC_19413703","title":"Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor.","date":"2009","source":"Obesity reviews : an official journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/19413703","citation_count":56,"is_preprint":false},{"pmid":"12671035","id":"PMC_12671035","title":"Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12671035","citation_count":56,"is_preprint":false},{"pmid":"12810820","id":"PMC_12810820","title":"PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12810820","citation_count":53,"is_preprint":false},{"pmid":"10357844","id":"PMC_10357844","title":"Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10357844","citation_count":49,"is_preprint":false},{"pmid":"15863365","id":"PMC_15863365","title":"Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15863365","citation_count":49,"is_preprint":false},{"pmid":"16960448","id":"PMC_16960448","title":"Statins of different brain penetrability differentially affect CSF PLTP activity.","date":"2006","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/16960448","citation_count":48,"is_preprint":false},{"pmid":"10681407","id":"PMC_10681407","title":"PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance.","date":"2000","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10681407","citation_count":48,"is_preprint":false},{"pmid":"9469594","id":"PMC_9469594","title":"Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I.","date":"1998","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/9469594","citation_count":47,"is_preprint":false},{"pmid":"32672883","id":"PMC_32672883","title":"The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32672883","citation_count":46,"is_preprint":false},{"pmid":"21782857","id":"PMC_21782857","title":"PLTP regulates STAT3 and NFκB in differentiated THP1 cells and human monocyte-derived macrophages.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21782857","citation_count":44,"is_preprint":false},{"pmid":"15795933","id":"PMC_15795933","title":"Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.","date":"2005","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/15795933","citation_count":43,"is_preprint":false},{"pmid":"17553507","id":"PMC_17553507","title":"Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17553507","citation_count":42,"is_preprint":false},{"pmid":"22897926","id":"PMC_22897926","title":"The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism.","date":"2012","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22897926","citation_count":42,"is_preprint":false},{"pmid":"11123937","id":"PMC_11123937","title":"Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11123937","citation_count":41,"is_preprint":false},{"pmid":"22367708","id":"PMC_22367708","title":"Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22367708","citation_count":41,"is_preprint":false},{"pmid":"12893687","id":"PMC_12893687","title":"Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12893687","citation_count":40,"is_preprint":false},{"pmid":"23303044","id":"PMC_23303044","title":"Increased amyloid-β peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23303044","citation_count":36,"is_preprint":false},{"pmid":"11566452","id":"PMC_11566452","title":"The role of plasma phospholipid transfer protein (PLTP) in HDL remodeling in acute-phase patients.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11566452","citation_count":35,"is_preprint":false},{"pmid":"19100548","id":"PMC_19100548","title":"Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19100548","citation_count":35,"is_preprint":false},{"pmid":"24513285","id":"PMC_24513285","title":"Phospholipid transfer protein (PLTP) deficiency impaired blood-brain barrier integrity by increasing cerebrovascular oxidative stress.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24513285","citation_count":34,"is_preprint":false},{"pmid":"24532668","id":"PMC_24532668","title":"Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24532668","citation_count":33,"is_preprint":false},{"pmid":"12754275","id":"PMC_12754275","title":"Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12754275","citation_count":32,"is_preprint":false},{"pmid":"28596518","id":"PMC_28596518","title":"Recombinant human plasma phospholipid transfer protein (PLTP) to prevent bacterial growth and to treat sepsis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28596518","citation_count":31,"is_preprint":false},{"pmid":"11254899","id":"PMC_11254899","title":"Acute-phase HDL in phospholipid transfer protein (PLTP)-mediated HDL conversion.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11254899","citation_count":31,"is_preprint":false},{"pmid":"34974028","id":"PMC_34974028","title":"New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34974028","citation_count":30,"is_preprint":false},{"pmid":"36309086","id":"PMC_36309086","title":"PLTP is a p53 target gene with roles in cancer growth suppression and ferroptosis.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36309086","citation_count":30,"is_preprint":false},{"pmid":"29558025","id":"PMC_29558025","title":"Plasma lipid transfer proteins: The role of PLTP and CETP in atherogenesis.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29558025","citation_count":29,"is_preprint":false},{"pmid":"10191289","id":"PMC_10191289","title":"Phospholipid transfer protein (PLTP) causes proteolytic cleavage of apolipoprotein A-I.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10191289","citation_count":29,"is_preprint":false},{"pmid":"11290460","id":"PMC_11290460","title":"Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta-HDL generation.","date":"2001","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11290460","citation_count":29,"is_preprint":false},{"pmid":"12837855","id":"PMC_12837855","title":"PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12837855","citation_count":29,"is_preprint":false},{"pmid":"10487493","id":"PMC_10487493","title":"Serum phospholipid transfer protein activity and genetic variation of the PLTP gene.","date":"1999","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10487493","citation_count":26,"is_preprint":false},{"pmid":"18421000","id":"PMC_18421000","title":"Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18421000","citation_count":25,"is_preprint":false},{"pmid":"16388083","id":"PMC_16388083","title":"Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia.","date":"2005","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16388083","citation_count":25,"is_preprint":false},{"pmid":"12531890","id":"PMC_12531890","title":"Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12531890","citation_count":24,"is_preprint":false},{"pmid":"26160914","id":"PMC_26160914","title":"Phospholipid transfer protein (PLTP) deficiency accelerates memory dysfunction through altering amyloid precursor protein (APP) processing in a mouse model of Alzheimer's disease.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26160914","citation_count":23,"is_preprint":false},{"pmid":"11861670","id":"PMC_11861670","title":"Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11861670","citation_count":23,"is_preprint":false},{"pmid":"12177167","id":"PMC_12177167","title":"Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12177167","citation_count":22,"is_preprint":false},{"pmid":"17928634","id":"PMC_17928634","title":"Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17928634","citation_count":22,"is_preprint":false},{"pmid":"19446293","id":"PMC_19446293","title":"Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19446293","citation_count":22,"is_preprint":false},{"pmid":"25710294","id":"PMC_25710294","title":"Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25710294","citation_count":22,"is_preprint":false},{"pmid":"26258626","id":"PMC_26258626","title":"Cigarette smoke extract induces apoptosis of rat alveolar Type II cells via the PLTP/TGF-β1/Smad2 pathway.","date":"2015","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26258626","citation_count":21,"is_preprint":false},{"pmid":"22034170","id":"PMC_22034170","title":"Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: involvement of the Ras/ERK/PLTP pathway.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22034170","citation_count":21,"is_preprint":false},{"pmid":"29565987","id":"PMC_29565987","title":"PhosphoLipid transfer protein (PLTP) exerts a direct pro-inflammatory effect on rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) independently of its lipid transfer activity.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29565987","citation_count":21,"is_preprint":false},{"pmid":"17761633","id":"PMC_17761633","title":"Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17761633","citation_count":21,"is_preprint":false},{"pmid":"29883800","id":"PMC_29883800","title":"Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP).","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29883800","citation_count":20,"is_preprint":false},{"pmid":"9555005","id":"PMC_9555005","title":"Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9555005","citation_count":20,"is_preprint":false},{"pmid":"19948027","id":"PMC_19948027","title":"Plasma PLTP activity is inversely associated with HDL-C levels.","date":"2009","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19948027","citation_count":19,"is_preprint":false},{"pmid":"26320740","id":"PMC_26320740","title":"Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization.","date":"2015","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26320740","citation_count":18,"is_preprint":false},{"pmid":"15365582","id":"PMC_15365582","title":"Effects of weight loss on PLTP activity and HDL particle size.","date":"2004","source":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/15365582","citation_count":18,"is_preprint":false},{"pmid":"15832314","id":"PMC_15832314","title":"Phospholipid transfer protein (PLTP) mRNA expression is stimulated by developing embryos in the oviduct.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15832314","citation_count":17,"is_preprint":false},{"pmid":"33351780","id":"PMC_33351780","title":"Metabolism of PLTP, CETP, and LCAT on multiple HDL sizes using the Orbitrap Fusion Lumos.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33351780","citation_count":16,"is_preprint":false},{"pmid":"18826383","id":"PMC_18826383","title":"SAA and PLTP activity in plasma of periodontal patients before and after full-mouth tooth extraction.","date":"2008","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18826383","citation_count":16,"is_preprint":false},{"pmid":"21973210","id":"PMC_21973210","title":"Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity.","date":"2011","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21973210","citation_count":15,"is_preprint":false},{"pmid":"24121956","id":"PMC_24121956","title":"PLTP deficiency impairs learning and memory capabilities partially due to alteration of amyloid-β metabolism in old mice.","date":"2014","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/24121956","citation_count":15,"is_preprint":false},{"pmid":"31220615","id":"PMC_31220615","title":"Phospholipid transfer protein (PLTP) deficiency attenuates high fat diet induced obesity and insulin resistance.","date":"2019","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/31220615","citation_count":14,"is_preprint":false},{"pmid":"19321130","id":"PMC_19321130","title":"PLTP is present in the nucleus, and its nuclear export is CRM1-dependent.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19321130","citation_count":14,"is_preprint":false},{"pmid":"26009633","id":"PMC_26009633","title":"PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26009633","citation_count":14,"is_preprint":false},{"pmid":"11324722","id":"PMC_11324722","title":"Differential display reveals downregulation of the phospholipid transfer protein (PLTP) at the mRNA level in brains of patients with Down syndrome.","date":"2001","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11324722","citation_count":13,"is_preprint":false},{"pmid":"18711210","id":"PMC_18711210","title":"Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18711210","citation_count":13,"is_preprint":false},{"pmid":"10356658","id":"PMC_10356658","title":"Introduction of the human PLTP transgene suppresses the atherogenic diet-induced increase in plasma phospholipid transfer activity in C57BL/6 mice.","date":"1999","source":"International journal of clinical & laboratory research","url":"https://pubmed.ncbi.nlm.nih.gov/10356658","citation_count":12,"is_preprint":false},{"pmid":"36362012","id":"PMC_36362012","title":"Increased Weight Gain and Insulin Resistance in HF-Fed PLTP Deficient Mice Is Related to Altered Inflammatory Response and Plasma Transport of Gut-Derived LPS.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362012","citation_count":11,"is_preprint":false},{"pmid":"29731975","id":"PMC_29731975","title":"Deletion of plasma Phospholipid Transfer Protein (PLTP) increases microglial phagocytosis and reduces cerebral amyloid-β deposition in the J20 mouse model of Alzheimer's disease.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29731975","citation_count":11,"is_preprint":false},{"pmid":"12117557","id":"PMC_12117557","title":"Role of hepatic lipase and scavenger receptor BI in clearing phospholipid/free cholesterol-rich lipoproteins in PLTP-deficient mice.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12117557","citation_count":10,"is_preprint":false},{"pmid":"20534134","id":"PMC_20534134","title":"Human apoA-I increases macrophage foam cell derived PLTP activity without affecting the PLTP mass.","date":"2010","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/20534134","citation_count":9,"is_preprint":false},{"pmid":"23545183","id":"PMC_23545183","title":"High PLTP activity is associated with depressed left ventricular systolic function.","date":"2013","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/23545183","citation_count":9,"is_preprint":false},{"pmid":"23313246","id":"PMC_23313246","title":"Elevated expression of PLTP is atherogenic in apolipoprotein E deficient mice.","date":"2012","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/23313246","citation_count":8,"is_preprint":false},{"pmid":"21514421","id":"PMC_21514421","title":"Dry eye symptoms are increased in mice deficient in phospholipid transfer protein (PLTP).","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21514421","citation_count":8,"is_preprint":false},{"pmid":"21303701","id":"PMC_21303701","title":"Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21303701","citation_count":7,"is_preprint":false},{"pmid":"20667734","id":"PMC_20667734","title":"Synthesis of a series of novel 2,4,5-trisubstituted selenazole compounds as potential PLTP inhibitors.","date":"2010","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/20667734","citation_count":7,"is_preprint":false},{"pmid":"28012603","id":"PMC_28012603","title":"Overexpressed PLTP in macrophage may promote cholesterol accumulation by prolonged endoplasmic reticulum stress.","date":"2016","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/28012603","citation_count":7,"is_preprint":false},{"pmid":"20714154","id":"PMC_20714154","title":"Genetic association between PLTP gene polymorphisms and Alzheimer's disease in a Japanese population.","date":"2010","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/20714154","citation_count":6,"is_preprint":false},{"pmid":"17437182","id":"PMC_17437182","title":"Inducible expression of phospholipid transfer protein (PLTP) in transgenic mice: acute effects of PLTP on lipoprotein metabolism.","date":"2007","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/17437182","citation_count":6,"is_preprint":false},{"pmid":"30090492","id":"PMC_30090492","title":"Cigarette smoke extract induces the epithelial-to-mesenchymal transition via the PLTP/TGF-β1/Smad2 pathway in RLE-6TN cells.","date":"2016","source":"Toxicology research","url":"https://pubmed.ncbi.nlm.nih.gov/30090492","citation_count":4,"is_preprint":false},{"pmid":"19422933","id":"PMC_19422933","title":"Reduction of HDL levels lowers plasma PLTP and affects its distribution among lipoproteins in mice.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19422933","citation_count":4,"is_preprint":false},{"pmid":"35341274","id":"PMC_35341274","title":"AGTR1, PLTP, and SCG2 associated with immune genes and immune cell infiltration in calcific aortic valve stenosis: analysis from integrated bioinformatics and machine learning.","date":"2022","source":"Mathematical biosciences and engineering : MBE","url":"https://pubmed.ncbi.nlm.nih.gov/35341274","citation_count":3,"is_preprint":false},{"pmid":"40380281","id":"PMC_40380281","title":"DNA hypermethylation of PLTP mediated by DNMT3B aggravates vascular dysfunction in diabetic retinopathy via the AKT/GSK3β signaling pathway.","date":"2025","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/40380281","citation_count":2,"is_preprint":false},{"pmid":"27478449","id":"PMC_27478449","title":"Serum CETP and PLTP activity in middle-aged men living in urban or rural area of the Lower Silesia region. PURE Poland sub-study.","date":"2016","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/27478449","citation_count":2,"is_preprint":false},{"pmid":"21823416","id":"PMC_21823416","title":"[Study on the correlation between Chinese medical syndrome types and serum levels of PLTP and CETP in coronary heart disease patients].","date":"2011","source":"Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21823416","citation_count":1,"is_preprint":false},{"pmid":"41391040","id":"PMC_41391040","title":"Fibrates Inhibit PLTP-induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41391040","citation_count":0,"is_preprint":false},{"pmid":"34385888","id":"PMC_34385888","title":"Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations.","date":"2021","source":"Genetics research","url":"https://pubmed.ncbi.nlm.nih.gov/34385888","citation_count":0,"is_preprint":false},{"pmid":"39765303","id":"PMC_39765303","title":"Association of phospholipid transfer protein (PLTP) and the effect of genetic variant rs5072 on hypertriglyceridemia and atherogenic dyslipidemia in children and adolescents from Southeastern Mexico.","date":"2025","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39765303","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.21.25340771","title":"A sex-specific genome-wide association study of blood lipid levels in All of Us","date":"2025-11-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.21.25340771","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46807,"output_tokens":7336,"usd":0.12523},"stage2":{"model":"claude-opus-4-6","input_tokens":11101,"output_tokens":4423,"usd":0.24912},"total_usd":0.37435,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Recombinant human and mouse PLTP expressed in BHK cells possesses both phospholipid transfer activity and HDL conversion activity, demonstrating these are intrinsic functions of the PLTP protein. PLTP converts distinct HDL subspecies (Lp(A-I) and Lp(A-I/A-II)) into populations of larger and smaller particles.\",\n      \"method\": \"Eukaryotic cell expression of recombinant PLTP, functional assays for phospholipid transfer and HDL conversion\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted recombinant protein with direct functional assays, foundational study\",\n      \"pmids\": [\"7654777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PLTP binds to both apoA-I and apoA-II, and the PLTP-binding domain on apoA-I resides in the amino-terminal region (residues 27–141), as demonstrated by solid-phase ligand binding assay, ELISA, apolipoprotein affinity chromatography, and monoclonal antibody epitope mapping.\",\n      \"method\": \"Solid-phase ligand binding assay, ELISA, affinity chromatography, monoclonal antibody inhibition studies\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal binding methods in a single study\",\n      \"pmids\": [\"9469594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Molecular modeling of PLTP based on BPI crystal structure predicts a two-domain architecture with conserved N-terminal and C-terminal lipid-binding pockets. Site-directed mutagenesis of residues in these pockets abolishes phospholipid transfer activity. The N-terminal pocket mutants show reduced activity without altered HDL binding, while C-terminal pocket may mediate HDL association. A disulfide bridge between Cys146 and Cys185 is structurally essential.\",\n      \"method\": \"Homology modeling, site-directed mutagenesis, transient expression in HeLa cells, solid-phase HDL-binding assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis with functional assays, multiple orthogonal methods\",\n      \"pmids\": [\"10357844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PLTP has an inherent serine esterase-type protease activity that cleaves apoA-I in the C-terminal portion between residues Ala196 and Thr197, generating a 23 kDa N-terminal fragment. The cleavage is inhibited by APMSF and chymostatin, and is reproduced by recombinant PLTP from CHO cells and baculovirus-insect cell systems.\",\n      \"method\": \"SDS-PAGE, Western blot, mass spectrometry, N-terminal sequencing, protease inhibitor studies, recombinant PLTP\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assay with mass spectrometry confirmation and multiple recombinant sources\",\n      \"pmids\": [\"10191289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Phospholipid transfer by PLTP is a prerequisite for PLTP-mediated HDL conversion. Chemical modification (DEPC or EMTS) of PLTP reduces both phospholipid transfer and HDL conversion activities in parallel. Recombinant N-terminal pocket mutants defective in phospholipid transfer cannot release apoA-I from HDL3 or generate prebeta-HDL.\",\n      \"method\": \"Chemical modification of PLTP, recombinant mutant proteins, native gradient gel electrophoresis, ultracentrifugation, crossed immunoelectrophoresis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemical and genetic ablation of activity with multiple orthogonal readouts\",\n      \"pmids\": [\"11123937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human plasma PLTP exists as two distinct forms: a high-activity form (HA-PLTP, ~160 kDa) associated with apoE and a low-activity form (LA-PLTP, ~520 kDa) complexed with apoA-I. The two forms differ in heparin-binding affinity and can be separated chromatographically.\",\n      \"method\": \"Heparin-Sepharose chromatography, gel filtration, SDS-PAGE, Western blot, immunoprecipitation, anti-apoE and anti-apoA-I immunoaffinity chromatography\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal purification and identification methods\",\n      \"pmids\": [\"11854286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PLTP is a direct transcriptional target of LXR (liver X receptor): two functional LXR response elements (LXREs) were identified in the proximal promoter of the human PLTP gene, one a canonical DR4 and one a novel inverted repeat separated by 1 bp that also serves as an FXR response element.\",\n      \"method\": \"Affymetrix microarray, Northern blot, promoter LXRE characterization and reporter assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter elements characterized with multiple assays\",\n      \"pmids\": [\"12454263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HepG2-secreted PLTP co-elutes with apoE on gel filtration (~160 kDa), co-purifies with apoE on anti-apoE immunoaffinity chromatography, and anti-apoE antibodies inhibit PLTP activity, establishing a physical and functional interaction between PLTP and apoE in hepatic cells.\",\n      \"method\": \"Heparin-Sepharose affinity chromatography, size-exclusion chromatography, anti-apoE immunoaffinity chromatography, antibody inhibition of PLTP activity\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple chromatographic methods plus functional inhibition assay\",\n      \"pmids\": [\"12810820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mast cell chymase degrades PLTP into specific fragments (70, 52, 48, 31 kDa), reducing both PLTP-mediated phospholipid transfer activity and pre-beta-HDL generation. Chymase also degrades PLTP-generated pre-beta-HDL particles, impairing high-affinity cholesterol efflux from macrophage foam cells.\",\n      \"method\": \"Immunoblot, phospholipid transfer assay, native gel electrophoresis, cholesterol efflux assay from foam cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic cleavage with defined functional consequences at multiple endpoints\",\n      \"pmids\": [\"12531890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PLTP functions as a transfer factor for alpha-tocopherol (vitamin E) in the brain. PLTP-deficient mice show significant brain alpha-tocopherol depletion, elevated oxidative stress markers (lipofuscin, cholesterol oxides, cellular peroxides), and increased anxiety behavior, establishing PLTP's role in brain vitamin E transport.\",\n      \"method\": \"PLTP knockout mouse model, alpha-tocopherol quantification, lipofuscin and cholesterol oxide measurement, elevated plus-maze behavioral testing\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with multiple biochemical and behavioral readouts\",\n      \"pmids\": [\"15576481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Exogenous recombinant PLTP added to primary human astrocytes significantly increases apoE secretion into conditioned medium, demonstrating that PLTP can regulate apoE secretion in brain cells.\",\n      \"method\": \"Recombinant PLTP treatment of primary human astrocyte cultures, PLTP activity assay, anti-apoE immunoaffinity chromatography, Western blot\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cell treatment experiment with single functional readout\",\n      \"pmids\": [\"15795933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Phospholipid transfer activity of PLTP is essential for atherogenesis: mice expressing a mutant PLTP that associates with HDL but lacks transfer activity show no change in HDL lipids, no stimulation of hepatic VLDL-TG secretion, and no increase in atherosclerotic lesion size, unlike mice expressing wild-type PLTP.\",\n      \"method\": \"Transgenic mice expressing transfer-inactive PLTP mutant, plasma lipid measurements, VLDL secretion assay, atherosclerosis quantification\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with activity-null mutant, multiple phenotypic readouts\",\n      \"pmids\": [\"18711210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Elevation of systemic PLTP (transgenic overexpression) impairs macrophage reverse cholesterol transport (RCT) in vivo, reducing plasma and fecal 3H-cholesterol tracer levels. Elevation of macrophage-specific PLTP alone does not affect RCT, indicating the systemic PLTP pool drives the impairment.\",\n      \"method\": \"In vivo RCT assay with 3H-cholesterol-loaded macrophages, PLTP transgenic and macrophage transplantation models, radioactivity quantification in plasma/liver/feces\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo RCT assay with cell-specific transplantation controls\",\n      \"pmids\": [\"19100548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Acute elevation of plasma PLTP activity in LDLR-knockout mice inhibits VLDL catabolism (at least partly by decreasing lipoprotein lipase activity), increases plasma VLDL-triglyceride levels, decreases HDL, and accelerates progression and destabilization of pre-existing atherosclerotic lesions.\",\n      \"method\": \"Conditional Tet-On transgenic mouse model, VLDL secretion assay, lipoprotein lipase activity measurement, atherosclerosis quantification, lesion composition analysis\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible transgenic model with mechanistic VLDL/LPL readouts\",\n      \"pmids\": [\"18421000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PLTP localizes to the nucleus of neuroblastoma cells, cortical neurons, and transfected CHO/BHK cells. Nuclear export of PLTP is CRM1-dependent (blocked by leptomycin B). Secreted extracellular PLTP can enter cells and translocate to the nucleus, where it remains phospholipid transfer-active.\",\n      \"method\": \"Subcellular fractionation, leptomycin B inhibition, live-cell imaging, phospholipid transfer activity assay of nuclear fractions\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional assay and pharmacological inhibition, single lab\",\n      \"pmids\": [\"19321130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLTP (wild-type and lipid-transfer-inactive mutant PLTPM159E) increases nuclear levels of active pSTAT3(Tyr705) in macrophages via an ABCA1-dependent mechanism, and reduces nuclear NFκB p65 levels and pro-inflammatory cytokine secretion, demonstrating lipid-transfer-independent anti-inflammatory signaling.\",\n      \"method\": \"Recombinant wild-type and mutant PLTP treatment of differentiated THP1 cells and primary macrophages, nuclear fractionation, ABCA1 chemical inhibition and siRNA knockdown, ELISA for cytokines\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — activity-null mutant distinguishes lipid transfer from signaling, ABCA1 confirmed by two knockdown methods\",\n      \"pmids\": [\"21782857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Liver-specific PLTP expression in PLTP-null mice dramatically increases plasma non-HDL cholesterol, phospholipids, triglycerides, and apoB levels by enhancing VLDL lipidation in the hepatocyte microsomal lumen and increasing VLDL secretion, without affecting HDL lipids.\",\n      \"method\": \"Adenovirus-mediated liver-specific PLTP expression in PLTP-null mice, VLDL lipidation assay in hepatocyte microsomes, plasma VLDL secretion assay\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — organ-specific rescue experiment with direct mechanistic readout (microsomal VLDL lipidation)\",\n      \"pmids\": [\"22367708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin G (a serine protease) cleaves and inactivates PLTP in COPD bronchoalveolar lavage fluid. PLTP silencing (siRNA) in mice prior to LPS challenge increases ERK and NF-κB activation and pro-inflammatory cytokine levels; conversely, recombinant PLTP administration counters these effects, establishing an anti-inflammatory role for lung PLTP.\",\n      \"method\": \"BALF proteolytic activity assay, PLTP siRNA in mouse lungs, recombinant PLTP administration, ERK/NF-κB western blot, cytokine measurement, LPS lung injury model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — loss-of-function and gain-of-function in vivo with mechanistic pathway readout, cathepsin G identified as the protease\",\n      \"pmids\": [\"24532668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PLTP deficiency increases BBB permeability in mice, decreases tight junction proteins (occludin, ZO-1, claudin-5), and elevates cerebrovascular ROS and lipid peroxidation. Dietary vitamin E supplementation in PLTP-KO mice restores BBB integrity and tight junction protein expression by reducing oxidative stress, linking PLTP's vitamin E transfer activity to BBB maintenance.\",\n      \"method\": \"In vivo multiphoton imaging, Evans blue assay, western blot for tight junction proteins, ROS and lipid peroxidation measurements, vitamin E dietary supplementation rescue\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO phenotype with dietary rescue linking mechanism to vitamin E transfer\",\n      \"pmids\": [\"24513285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PLTP deficiency in APP/PS1ΔE9 Alzheimer's model mice increases β-secretase activity and expression of γ-secretase catalytic units, shifts APP processing toward the amyloidogenic pathway, increases soluble Aβ peptides, and accelerates memory dysfunction, placing PLTP as a regulator of APP processing.\",\n      \"method\": \"PLTP/APP/PS1 double-knockout mouse model, β- and γ-secretase activity assays, Aβ ELISA, western blot, Morris water maze\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with direct secretase activity measurement, single study\",\n      \"pmids\": [\"26160914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PLTP deficiency in mice shifts CD4+ Th0 cell polarization toward the anti-inflammatory Th2 phenotype and significantly decreases production of the pro-Th1 cytokine IL-18 by accessory cells, establishing PLTP as a regulator of adaptive immune T-helper cell polarization.\",\n      \"method\": \"PLTP-KO mouse model, contact hypersensitivity model (DNFB), flow cytometry for T-cell subsets, cytokine measurements\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined immunological readouts and in vivo challenge model, single lab\",\n      \"pmids\": [\"26320740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Electron microscopy reveals PLTP has a banana-shaped structure similar to CETP. PLTP penetrates into both HDL and LDL surfaces and forms a ternary PLTP-HDL-LDL complex, providing structural basis for the phospholipid transfer mechanism between lipoproteins.\",\n      \"method\": \"Electron microscopy (multiple EM techniques), single-particle analysis, lipoprotein interaction studies\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural EM study with functional interaction data, single study without mutagenesis validation\",\n      \"pmids\": [\"29883800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Both lipid-transfer-active and -inactive forms of recombinant PLTP directly stimulate pro-inflammatory cytokine production (IL-8, IL-6, VEGF, MMP3) and proliferation of rheumatoid arthritis fibroblast-like synoviocytes (FLS) via ABCA1 and STAT3 pathway activation, independently of lipid transfer activity.\",\n      \"method\": \"Recombinant active and inactive PLTP treatment of RA-FLS, ELISA for cytokines, 3H-thymidine proliferation assay, flow cytometry for ABCA1, STAT3 activation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — activity-null mutant used to dissect lipid transfer from signaling, multiple cytokine readouts\",\n      \"pmids\": [\"29565987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PLTP deficiency protects mice from high-fat-diet-induced obesity and insulin resistance by enhancing insulin receptor and Akt phosphorylation in liver, adipose, and muscle, increasing GLUT4 in plasma membranes of adipocytes and muscle cells after insulin stimulation, and reducing sphingomyelins and free cholesterol in lipid rafts of hepatocyte plasma membranes.\",\n      \"method\": \"PLTP-KO mice on high-fat diet, western blot for insulin receptor/Akt phosphorylation, GLUT4 plasma membrane fractionation, lipid raft lipid composition analysis\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO model with multiple mechanistic readouts including lipid raft composition, single lab\",\n      \"pmids\": [\"31220615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PLTP is identified as a batokine secreted by brown adipose tissue (BAT). Systemic or BAT-specific PLTP overexpression improves glucose tolerance, insulin sensitivity, and energy expenditure, and decreases plasma cholesterol/phospholipids/sphingolipids. The mechanism involves increased circulating bile acids that in turn enhance glucose uptake and thermogenesis in BAT, establishing PLTP as a mediator of BAT-liver interorgan communication.\",\n      \"method\": \"Proteomics/transcriptomics of human thermogenic adipocytes, BAT-specific and systemic PLTP overexpression mouse models, bile acid measurement, glucose tolerance and insulin sensitivity tests\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — organ-specific overexpression with multi-organ metabolic readouts and identification of bile acid intermediary\",\n      \"pmids\": [\"32672883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLTP is a direct transcriptional target of p53; its transactivation is impaired by cancer-associated p53 hypomorphs (P47S, Y107H, G334R). Enforced PLTP expression suppresses colony formation in human tumor cell lines and regulates cellular sensitivity to ferroptosis.\",\n      \"method\": \"RNA-seq in lymphoblastoid cell lines, p53 hypomorph comparison, PLTP overexpression colony formation assay, ferroptosis sensitivity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple p53 hypomorphs tested, direct p53-PLTP transcriptional link with functional cancer readouts\",\n      \"pmids\": [\"36309086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CSE-induced TGF-β1 production and Smad3 phosphorylation in human alveolar epithelial cells is mediated through a Ras/ERK/PLTP pathway: ERK inhibition suppresses PLTP expression and TGF-β1 production; PLTP siRNA suppresses TGF-β1 and Smad3 activation downstream of ERK, without affecting Ras/ERK itself.\",\n      \"method\": \"ERK inhibitors, PLTP siRNA, Smad3 phosphorylation western blot, TGF-β1 ELISA in A549 cells\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by siRNA at defined pathway position, single lab\",\n      \"pmids\": [\"22034170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In vivo tracer studies using Orbitrap Lumos mass spectrometry show that PLTP is secreted in medium and large HDL (alpha2, alpha1, alpha0) and is transferred from medium to larger HDL sizes during circulation, from where it is catabolized.\",\n      \"method\": \"In vivo stable isotope tracer kinetics, targeted mass spectrometry (Orbitrap Lumos), compartmental modeling\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — in vivo metabolic tracing with compartmental modeling, novel metabolic pathway placement\",\n      \"pmids\": [\"33351780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In diabetic retinopathy, PLTP promoter DNA hypermethylation mediated by DNMT3B suppresses PLTP expression in retinal endothelial cells. PLTP overexpression reverses high-glucose-induced impairment of endothelial migration and tube formation by promoting AKT and GSK3β phosphorylation, identifying PLTP as a regulator of retinal vascular function via the AKT/GSK3β pathway.\",\n      \"method\": \"siRNA for DNMT3B, luciferase reporter assay, PLTP overexpression in HRMECs, tube formation/migration assays, coimmunoprecipitation, GSK3β inhibitor, transcriptome sequencing\",\n      \"journal\": \"Clinical epigenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single study identifying DNMT3B as writer and AKT/GSK3β as downstream pathway\",\n      \"pmids\": [\"40380281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLTP promotes M2 macrophage polarization in hepatocellular carcinoma by binding to AURKA and p65, forming a ternary complex that induces p65 phosphorylation, activating NF-κB and upregulating IL-6, IL-8, and CSF-1. The PLTP functional domain (residues 25–245) mediates these interactions.\",\n      \"method\": \"Molecular docking, proteomics, coimmunoprecipitation, biochemical assays, PLTP overexpression in HCC, in vivo mouse models\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and molecular docking with in vivo validation, single lab\",\n      \"pmids\": [\"41391040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ApoA-I (and apolipoproteins E, A-II, A-IV) enhances PLTP phospholipid transfer activity in a concentration-dependent manner without affecting PLTP secretion or mass from macrophage foam cells, and protects PLTP from heat inactivation.\",\n      \"method\": \"THP-1 macrophage foam cell model, PLTP activity assay, PLTP mass ELISA, recombinant apolipoprotein addition\",\n      \"journal\": \"Lipids in health and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — cell culture experiment with activity readout, mechanism of activation not fully resolved\",\n      \"pmids\": [\"20534134\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLTP is a plasma glycoprotein with a two-domain, lipid-binding-pocket structure (similar to BPI/CETP) that transfers phospholipids between lipoproteins by forming ternary PLTP-HDL-LDL complexes; its N-terminal pocket drives phospholipid transfer (a prerequisite for HDL conversion into larger fusion particles and prebeta-HDL), while its C-terminal pocket mediates HDL binding via apoA-I (residues 27–141) and apoE; PLTP circulates as a high-activity (~160 kDa, apoE-associated) and a low-activity (~520 kDa, apoA-I-associated) form, is a direct transcriptional target of LXR, FXR, and p53, drives hepatic VLDL production, transfers alpha-tocopherol to the brain and across the BBB, neutralizes and transfers LPS to lipoproteins, activates STAT3 and suppresses NF-κB in macrophages via ABCA1 in a lipid-transfer-independent manner, modulates CD4+ T-helper cell polarization, and in cancer contexts promotes NF-κB activation through a PLTP-AURKA-p65 complex and regulates ferroptosis sensitivity downstream of p53.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PLTP is a secreted lipid transfer glycoprotein that shuttles phospholipids and alpha-tocopherol between lipoproteins and across tissue barriers, functioning as a central regulator of HDL remodeling, hepatic VLDL assembly, brain vitamin E homeostasis, and innate/adaptive immune signaling. Its banana-shaped, two-domain architecture contains an N-terminal lipid-binding pocket essential for phospholipid transfer—a prerequisite for HDL conversion into larger fusion particles and prebeta-HDL generation—and a C-terminal pocket that mediates HDL association via apoA-I (residues 27–141) and apoE, with PLTP circulating as a high-activity (~160 kDa, apoE-associated) and a low-activity (~520 kDa, apoA-I-associated) form [PMID:10357844, PMID:11123937, PMID:9469594, PMID:11854286, PMID:29883800]. Beyond lipid transfer, PLTP activates STAT3 and suppresses NF-κB in macrophages through an ABCA1-dependent, lipid-transfer-independent signaling mechanism, modulates CD4+ T-helper cell polarization, and in hepatocellular carcinoma forms a ternary complex with AURKA and NF-κB p65 to drive pro-inflammatory cytokine expression [PMID:21782857, PMID:26320740, PMID:41391040]. PLTP is transcriptionally regulated by LXR, FXR, and p53, and its expression is epigenetically silenced by DNMT3B-mediated promoter hypermethylation in diabetic retinopathy, where it promotes endothelial function via AKT/GSK3β signaling [PMID:12454263, PMID:36309086, PMID:40380281].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that phospholipid transfer and HDL conversion are intrinsic activities of the PLTP protein resolved whether these were separable plasma functions or properties of a single gene product.\",\n      \"evidence\": \"Recombinant human/mouse PLTP expressed in BHK cells reconstituted both activities in vitro\",\n      \"pmids\": [\"7654777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for dual activity unknown\", \"Relationship between phospholipid transfer and HDL conversion not yet causally ordered\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping the PLTP-binding domain on apoA-I to residues 27–141 identified the molecular interface through which PLTP engages its principal HDL-associated apolipoprotein partner.\",\n      \"evidence\": \"Solid-phase binding, ELISA, affinity chromatography, and monoclonal antibody epitope mapping\",\n      \"pmids\": [\"9469594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reciprocal mapping of the apoA-I-binding site on PLTP not determined\", \"Structural resolution of the PLTP–apoA-I complex lacking\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Homology modeling and site-directed mutagenesis established PLTP's two-domain BPI-like architecture and demonstrated that both N- and C-terminal lipid-binding pockets are functionally required, with the N-terminal pocket driving phospholipid transfer and the C-terminal pocket mediating HDL binding.\",\n      \"evidence\": \"Structure-guided mutagenesis of lipid-pocket residues in HeLa-expressed PLTP, solid-phase HDL-binding assay\",\n      \"pmids\": [\"10357844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of PLTP itself\", \"Contribution of the C-terminal pocket to transfer vs. binding not fully delineated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery of an intrinsic serine esterase-type protease activity in PLTP that cleaves apoA-I at Ala196–Thr197 revealed an unexpected catalytic function beyond lipid transfer.\",\n      \"evidence\": \"Mass spectrometry, N-terminal sequencing, and protease inhibitor studies on recombinant PLTP from multiple expression systems\",\n      \"pmids\": [\"10191289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of apoA-I cleavage in vivo undetermined\", \"Active-site residues responsible for protease activity not identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that phospholipid transfer is a prerequisite for HDL conversion causally ordered PLTP's two activities: lipid transfer must occur before apoA-I release and prebeta-HDL generation.\",\n      \"evidence\": \"Chemical modification and N-terminal pocket mutants abolished both transfer and HDL conversion in parallel\",\n      \"pmids\": [\"11123937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetic mechanism of coupled transfer-to-conversion not resolved\", \"Whether intermediate lipid species are required not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolution of two circulating PLTP forms—a high-activity ~160 kDa apoE-associated form and a low-activity ~520 kDa apoA-I-associated form—explained the long-standing discrepancy between PLTP mass and activity measurements in plasma.\",\n      \"evidence\": \"Heparin-Sepharose and gel filtration chromatography, immunoaffinity separation with anti-apoE/anti-apoA-I\",\n      \"pmids\": [\"11854286\", \"12810820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What converts HA-PLTP to LA-PLTP is unknown\", \"Whether the two forms have distinct tissue origins not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of functional LXR and FXR response elements in the PLTP promoter placed PLTP under direct nuclear receptor transcriptional control, connecting its expression to cholesterol/bile acid sensing.\",\n      \"evidence\": \"Microarray, Northern blot, and promoter-reporter assays in human cells\",\n      \"pmids\": [\"12454263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific transcriptional regulation not fully characterized\", \"Relative contribution of LXR vs. FXR in different tissues unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"PLTP-knockout mice revealed a non-redundant role for PLTP in brain alpha-tocopherol delivery, with deficiency causing vitamin E depletion, oxidative stress, and behavioral abnormalities.\",\n      \"evidence\": \"PLTP-KO mouse model with alpha-tocopherol quantification, oxidative stress markers, and elevated plus-maze testing\",\n      \"pmids\": [\"15576481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PLTP transfers vitamin E across the BBB directly or via lipoproteins not resolved\", \"CNS cell types responsible for PLTP-mediated vitamin E transport not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"In vivo studies using transfer-inactive PLTP mutant mice and PLTP transgenic mice established that phospholipid transfer activity is required for PLTP's pro-atherogenic effects including stimulation of hepatic VLDL secretion, impairment of reverse cholesterol transport, and atherosclerotic lesion progression.\",\n      \"evidence\": \"Transfer-inactive PLTP mutant transgenic mice, PLTP overexpression models, in vivo RCT assay, VLDL secretion, and atherosclerosis quantification\",\n      \"pmids\": [\"18711210\", \"19100548\", \"18421000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which PLTP stimulates VLDL lipidation not resolved at the protein level\", \"Whether transfer activity is also required for anti-inflammatory signaling not tested in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstration that both active and transfer-inactive PLTP activate STAT3 and suppress NF-κB in macrophages via ABCA1 uncovered a lipid-transfer-independent signaling function, separating PLTP's metabolic and immunomodulatory roles.\",\n      \"evidence\": \"Wild-type and M159E mutant PLTP treatment of THP1 and primary macrophages, ABCA1 siRNA and chemical inhibition, nuclear fractionation\",\n      \"pmids\": [\"21782857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PLTP engages ABCA1 to activate STAT3 mechanistically unknown\", \"Whether this signaling operates in vivo under physiological conditions not shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Liver-specific PLTP rescue in PLTP-null mice showed that hepatic PLTP drives VLDL lipidation in the microsomal lumen and VLDL secretion without affecting HDL, establishing the liver as the primary tissue for PLTP's pro-atherogenic VLDL effects.\",\n      \"evidence\": \"Adenovirus-mediated liver-specific PLTP expression, hepatocyte microsomal VLDL lipidation assay\",\n      \"pmids\": [\"22367708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PLTP acts on apoB directly or via an intermediary lipid donor in the ER lumen unknown\", \"Contribution of intestinal PLTP to VLDL metabolism not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"In vivo loss- and gain-of-function experiments in lung established PLTP as an anti-inflammatory factor degraded by cathepsin G in COPD, bridging PLTP's lipid transfer function with innate immune regulation in the airway.\",\n      \"evidence\": \"PLTP siRNA and recombinant PLTP in mouse LPS lung injury model, cathepsin G cleavage of PLTP in BALF\",\n      \"pmids\": [\"24532668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether anti-inflammatory lung function is lipid-transfer-dependent or ABCA1/STAT3-dependent not distinguished\", \"PLTP's substrate in the lung (LPS, surfactant phospholipids) not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking PLTP deficiency to BBB breakdown via reduced tight junction proteins and oxidative stress—rescued by dietary vitamin E—provided a mechanistic chain from PLTP's vitamin E transfer activity to cerebrovascular integrity.\",\n      \"evidence\": \"Multiphoton imaging, Evans blue permeability assay, tight junction protein western blot, vitamin E dietary rescue in PLTP-KO mice\",\n      \"pmids\": [\"24513285\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct measurement of PLTP-mediated vitamin E transport across BBB endothelium not performed\", \"Whether tight junction loss is a direct or secondary consequence of oxidative stress not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PLTP deficiency shifted CD4+ T-helper polarization toward Th2 and reduced IL-18, establishing PLTP as a modulator of adaptive immunity beyond its known innate immune roles.\",\n      \"evidence\": \"PLTP-KO mouse contact hypersensitivity model, flow cytometry for T-cell subsets, cytokine measurements\",\n      \"pmids\": [\"26320740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether effect on Th polarization is cell-autonomous or mediated by accessory cell lipid changes not resolved\", \"Molecular mechanism linking PLTP to IL-18 production unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Electron microscopy visualization of PLTP's banana-shaped structure and its ternary complex with HDL and LDL provided the first direct structural basis for the shuttle transfer mechanism between lipoproteins.\",\n      \"evidence\": \"Single-particle EM analysis of PLTP and PLTP–lipoprotein complexes\",\n      \"pmids\": [\"29883800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Atomic-resolution structure not available\", \"Whether the ternary complex is an obligate intermediate or one of multiple transfer modes not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of PLTP as a batokine secreted by brown adipose tissue that improves systemic glucose tolerance through bile acid-mediated interorgan signaling expanded PLTP's metabolic role beyond lipoprotein metabolism.\",\n      \"evidence\": \"Proteomics of human thermogenic adipocytes, BAT-specific PLTP overexpression mice, bile acid measurements, glucose tolerance tests\",\n      \"pmids\": [\"32672883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which PLTP increases bile acid levels not determined\", \"Whether BAT-derived PLTP acts on hepatic VLDL secretion not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing PLTP as a direct p53 transcriptional target that suppresses colony formation and regulates ferroptosis sensitivity connected PLTP to tumor suppression pathways beyond lipid metabolism.\",\n      \"evidence\": \"RNA-seq in lymphoblastoid cell lines with p53 hypomorphs, PLTP overexpression colony formation and ferroptosis assays\",\n      \"pmids\": [\"36309086\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of ferroptosis regulation by PLTP (lipid peroxidation vs. iron) not resolved\", \"Whether PLTP tumor-suppressive function operates in vivo not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery of a PLTP–AURKA–p65 ternary complex that activates NF-κB in hepatocellular carcinoma revealed that PLTP can also promote—not just suppress—NF-κB signaling in a context-dependent manner, driving M2 macrophage polarization and tumor-associated inflammation.\",\n      \"evidence\": \"Reciprocal co-IP, molecular docking, proteomics, PLTP overexpression in HCC cells and mouse tumor models\",\n      \"pmids\": [\"41391040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Apparent contradiction with anti-inflammatory NF-κB suppression in macrophages not reconciled\", \"Whether AURKA kinase activity is required for the PLTP-mediated p65 activation not tested\", \"Single-lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of DNMT3B-mediated promoter hypermethylation as a mechanism silencing PLTP in diabetic retinopathy, with downstream AKT/GSK3β signaling rescuing endothelial dysfunction, added an epigenetic regulatory layer to PLTP biology.\",\n      \"evidence\": \"DNMT3B siRNA, luciferase reporter, PLTP overexpression in HRMECs, tube formation/migration assays\",\n      \"pmids\": [\"40380281\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PLTP activates AKT directly or through an intermediary receptor unknown\", \"In vivo validation in diabetic retinopathy models not reported\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The atomic-resolution structure of PLTP, the mechanism by which PLTP engages ABCA1 to trigger STAT3 signaling independently of lipid transfer, and the basis for context-dependent NF-κB activation versus suppression remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution crystal or cryo-EM structure of human PLTP\", \"ABCA1–PLTP signaling interface uncharacterized\", \"Context determinants for pro- vs. anti-inflammatory NF-κB outcomes unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 2, 4, 9, 11]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 4, 16]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [15, 22, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 5, 7, 21, 27]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 4, 5, 9, 11, 16, 24, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 22, 26, 28, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 20, 29]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APOA1\", \"APOE\", \"ABCA1\", \"AURKA\", \"RELA\"],\n    \"other_free_text\": []\n  }\n}\n```"}